Compare ThredUp Inc (TDUP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ThredUp Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? ThredUp Inc trades at $2.47 (market cap $308.63M), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 413.3× ThredUp Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ThredUp Inc for 29 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TDUP | VRTX | |
|---|---|---|
Market Cap | $308.63M | $127.55B |
Volume | 3,024,364 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.41 | $557.96 |
52-Week Low | $2.12 | $407.37 |
Typical Hold Time | 29 Days | 120 Days |
Enterprise Value | $306.81M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ThredUp (TDUP) trades at $2.455, up 10.59% in the past 24 hours, with a bearish technical signal but strong analyst support. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed earnings expectations with a net loss. Fundamentals show a high gross margin of 79.52% but negative net income margin and ROE, while cash flow from operations improved to $10.65 million in 2025.
The outlook is mixed: analyst consensus is 57% buy with no sell ratings, but profitability remains a challenge amid promotional headwinds. Risks include ongoing losses, competitive pressures, and a recent stock decline following guidance cuts. Investment opportunity hinges on execution toward profitability despite current bearish technicals.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
